Osmyn Lavor Deuel v. HHS - Tdap, Guillain-Barré Syndrome (GBS) or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (2025)
Case summary [AI summaries can sometimes make mistakes]
Osmyn Lavor Deuel filed a petition on July 28, 2022, alleging that the tetanus-diphtheria-acellular pertussis (Tdap) vaccine he received on August 1, 2019, caused him to suffer from Guillain-Barré Syndrome (GBS) or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The Tdap vaccine is listed on the Vaccine Injury Table.
Respondent denied that the vaccine caused Mr. Deuel's condition but agreed to a joint stipulation for compensation.
The parties stipulated to an award of $80,000.00 to compensate Mr. Deuel for all damages available under the program.
Special Master Christian J. Moran found the stipulation reasonable and adopted it as the decision of the Court, directing that judgment be entered accordingly.
The public decision does not describe the onset of symptoms, specific medical tests, treatments, or expert witnesses. Petitioner was represented by David Charles Richards of Christensen & Jensen, P.C., and Respondent was represented by Nina Ren of the United States Department of Justice.
Theory of causation
Petitioner Osmyn Lavor Deuel alleged that the Tdap vaccine received on August 1, 2019, caused Guillain-Barré Syndrome (GBS) or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The Tdap vaccine is listed on the Vaccine Injury Table. Respondent denied causation. The parties entered into a joint stipulation for compensation, agreeing to an award of $80,000.00 for all damages. Special Master Christian J. Moran adopted the stipulation as the decision of the Court on April 1, 2025. The public decision does not detail the specific mechanism of causation, expert testimony, or the breakdown of damages beyond the lump sum. Petitioner's counsel was David Charles Richards, and Respondent's counsel was Nina Ren.
Source PDFs
USCOURTS-cofc-1_22-vv-00830